

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Term	Documents
(3 AND 4).DWPI.	3

Database:

US Patents Full-Text Database	▲
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Refine Search:

13 and 14	▲
	▼

[Clear](#)

Search History**Today's Date: 6/8/2000**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
DWPI	13 and 14	3	<u>L5</u>
DWPI	lung or pulmonary or inhal\$6	21948	<u>L4</u>
DWPI	11 or 12	62	<u>L3</u>
DWPI	glucagon adj like adj peptide adj (1 or i)	45	<u>L2</u>
DWPI	(glp adj (1 or i))	52	<u>L1</u>

WEST

Generate Collection

Search Results - Record(s) 1 through 3 of 3 returned.

- ☐ 1. Document ID: AU 9926596 A, WO 9940788 A1
L7: Entry 1 of 3 File: DWPI Aug 30, 1999
- DERWENT-ACC-NO: 1999-527332
DERWENT-WEEK: 200003
COPYRIGHT 2000 DERWENT INFORMATION LTD
- TITLE: Increasing urine flow by administering peptides or peptide agonists
L7: Entry 1 of 3 File: DWPI Aug 30, 1999
- DERWENT-ACC-NO: 1999-527332
DERWENT-WEEK: 200003
COPYRIGHT 2000 DERWENT INFORMATION LTD
- TITLE: Increasing urine flow by administering peptides or peptide agonists
- ABTX:
NOVELTY - Increasing urine flow (I) in an individual comprising administering an exendin or exendin agonist, or a GLP-1 (glucagon-like peptide) or GLP-1 agonist.
- ABTX:
(1) decreasing the concentration of potassium (II) in an individual's urine, comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;
- ABTX:
(2) preventing or alleviating a condition/disorder associated with toxic hypervolemia (III), comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;
- ABTX:
(3) inducing rapid diuresis (IV) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;
- ABTX:
(4) preparing an individual for a surgical procedure (V) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;
- ABTX:
(5) increasing renal plasma flow and glomerular filtration rate (VI) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;
- ABTX:
(6) treating pre-eclampsia or eclampsia of pregnancy (VII) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;
- ABTX:
(7) increasing cardiac contractility (VIII) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist;
- ABTX:
(8) treating a condition or disorder that can be alleviated by increasing cardiac contractility (XI) comprising administering an exendin or exendin agonist, or GLP-1 or a GLP-1 agonist; and
- ABTX:
(9) pharmaceutical compositions containing an exendin or exendin agonist, or a

(9) pharmaceutical compositions containing an exendin or exendin agonist, or a GLP-1 or a GLP-1 agonist, for use in all the above methods.

ABTX:

MECHANISM OF ACTION - GLP-1 stimulates insulin secretion from pancreatic cells.

ABTX:

USE - The new methods using an exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for increasing urine flow, decreasing potassium concentration in urine, preventing or alleviating a disorder associated with toxic hypervolemia, inducing rapid diuresis, preparing an individual for surgical procedure, increasing renal plasma flow and glomerular filtration rate, treating pre-eclampsia or eclampsia of pregnancy, and increasing a condition/disorder that can be alleviated by increasing cardiac contractility (claimed). Method (III) is useful for treating or alleviating renal failure, congestive heart failure, nephrotic syndrome, pulmonary edema and cirrhosis, or preferably hypertension. Method (IX) is useful for treating congestive heart failure, pulmonary edema, systemic edema or renal failure (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------	-------

☐ 2. Document ID: EP 941114 A1, WO 9820895 A1, ZA 9710182 A, AU 9748637 A

L7: Entry 2 of 3

File: DWPI

Sep 15, 1999

DERWENT-ACC-NO: 1998-297611

DERWENT-WEEK: 199942

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Treatment of diseases associated with impaired appetite regulation e.g. obesity - by administration of the proglucagon fragment GLP-1(1-45), or its fragment, analogue or amide

L7: Entry 2 of 3

File: DWPI

Sep 15, 1999

DERWENT-ACC-NO: 1998-297611

DERWENT-WEEK: 199942

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Treatment of diseases associated with impaired appetite regulation e.g. obesity - by administration of the proglucagon fragment GLP-1(1-45), or its fragment, analogue or amide

ABTX :

Treatment or prevention of diseases or disorders associated with impaired appetite regulation or feeling of satiety comprises administration of (i) GLP-1(1-45) (where GLP-1 is glucagon-like peptide-1), (ii) a fragment or analogue of GLP-1(1-45), or (iii) a C-terminal amide of a compound as described in (i) or (ii).

ABTX:

USE - The process may be used e.g. in treatment of obesity. Administration is especially parenteral, nasal, pulmonary, transdermal, rectal, buccal or vaginal. Dosage of active agent is 10 mu g/kg/day to 5 mg/kg/day.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWC	Draw. Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	------------	-------

☐ 3. Document ID: WO 9001540 A, AU 8942166 A, CA 1320162 C, EP 428615 A, EP 428615 A4, JP 04501204 W

L7: Entry 3 of 3

File: DWPI

Feb 22, 1990

